Alpha Cognition Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Alpha Cognition Inc. (ACOG) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$8.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-13
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$8.79M.
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$7.03M.
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$6.80M.
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$4.99M.
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$20.85M.
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$14.79M.
- Alpha Cognition Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$13.76M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.79M 10-Q · filed 2026-08-13 | -$15.63M 10-Q · filed 2026-08-13 | -$22.62M derived: sum of 3 quarters · filed 2026-08-13 | -$27.61M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$7.03M 10-Q · filed 2026-05-14 | -$13.83M derived: sum of 2 quarters · filed 2026-05-14 | -$18.82M derived: sum of 3 quarters · filed 2026-05-14 | -$32.02M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$11.79M derived: sum of 2 quarters · filed 2026-03-31 | -$24.99M derived: sum of 3 quarters · filed 2026-08-13 | -$20.85M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$4.99M 10-Q · filed 2025-11-13 | -$18.18M derived: sum of 2 quarters · filed 2026-08-13 | -$14.05M 10-Q · filed 2025-11-13 | -$25.72M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | -$13.20M 10-Q · filed 2026-08-13 | -$10.49M 10-Q · filed 2025-08-14 | -$14.92M 10-Q · filed 2026-08-13 | -$12.50M 10-Q · filed 2025-08-14 | -$20.73M derived: sum of 3 quarters · filed 2026-08-13 | -$22.59M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$1.73M 10-Q · filed 2026-05-14 | -$2.01M 10-Q · filed 2025-05-15 | -$7.54M derived: sum of 2 quarters · filed 2026-05-14 | -$9.40M derived: sum of 3 quarters · filed 2026-05-14 | -$11.51M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$7.67M derived: sum of 2 quarters · filed 2026-03-31 | -$9.79M derived: sum of 3 quarters · filed 2026-03-31 | -$14.79M 10-K · filed 2026-03-31 | -$14.64M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | -$1.86M 10-Q · filed 2025-11-13 | -$3.98M derived: sum of 2 quarters · filed 2025-11-13 | -$8.98M 10-Q · filed 2025-11-13 | -$14.69M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$2.12M 10-Q · filed 2025-08-14 | -$7.12M 10-Q · filed 2025-08-14 | -$12.83M derived: sum of 3 quarters · filed 2025-08-14 | -$16.10M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$5.00M 10-Q · filed 2025-05-15 | -$10.72M derived: sum of 2 quarters · filed 2025-05-15 | -$13.99M derived: sum of 3 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$8.98M derived: sum of 2 quarters · filed 2025-03-31 | -$13.76M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$3.27M 10-Q · filed 2024-11-14 | -$8.05M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |